Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms

Einama,Takahiro; Kamachi,Hirofumi; Nishihara,Hiroshi; Homma,Shigenori; Kanno,Hiromi; Ishikawa,Marin; Kawamata,Futoshi; Konishi,Yuji; Sato,Masanori; Tahara,Munenori; Okada,Kuniaki; Muraoka,Shunji; Kamiyama,Toshiya; Taketomi,Akinobu; Matsuno,Yoshihiro; Furukawa,Hiroyuki; Todo,Satoru

doi:10.3892/ol.2015.2969

Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms

Authors:
- Takahiro Einama
- Hirofumi Kamachi
- Hiroshi Nishihara
- Shigenori Homma
- Hiromi Kanno
- Marin Ishikawa
- Futoshi Kawamata
- Yuji Konishi
- Masanori Sato
- Munenori Tahara
- Kuniaki Okada
- Shunji Muraoka
- Toshiya Kamiyama
- Akinobu Taketomi
- Yoshihiro Matsuno
- Hiroyuki Furukawa
- Satoru Todo
View Affiliations

Affiliations: Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan, Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan, Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060‑8638, Japan, Department of Pathology, Laboratory of Cancer Research, Hokkaido University School of Medicine, Sapporo, Hokkaido 060‑8638, Japan, Department of Surgery, JA Sapporo Kosei Hospital, Sapporo, Hokkaido 060‑0033, Japan, Department of Pathology, JA Sapporo Kosei Hospital, Sapporo, Hokkaido 060‑0033, Japan, Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Hokkaido 060‑8638, Japan, Division of Gastroenterological and General Surgery, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan
Published online on: February 17, 2015 https://doi.org/10.3892/ol.2015.2969
Pages: 1583-1589
Copyright: © Einama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of mesothelin expression in IPMN was performed in the present study, focusing on the localization of mesothelin. IPMNs were classified into two groups, IPMNs associated with invasive carcinoma and low‑high (L‑H) grade dysplasias. The tumors were classified as mesothelin‑positive or ‑negative and in the mesothelin‑positive cases, the localization of mesothelin was evaluated as luminal membrane‑ or cytoplasmic‑positive. Among the 37 IPMNs, mesothelin expression was observed in 21 samples (56.8%), including 46.2% (12 out of 26) of the L‑H dysplasia and 81.8% (9 out of 11) of the invasive carcinoma samples (P=0.071). Luminal membrane localization was observed in 10 samples (27%), including 15.4% (4/26) of the L‑H dysplasia samples and 54.5% (6 out of 11) of the invasive carcinoma samples (P=0.022). Six patients experienced post‑operative recurrence, with five of the recurrent tumors exhibiting mesothelin expression and all six exhibiting luminal membrane localization. It was concluded that immunohistochemical examinations for mesothelin expression and localization are clinically useful for prognostic assessments and decision making regarding further treatment subsequent to surgical procedures in patients with IPMN.

View Figures

View References

1	Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 93:136–140. 1996. View Article : Google Scholar : PubMed/NCBI
2	Chang K, Pastan I and Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 50:373–381. 1992. View Article : Google Scholar : PubMed/NCBI
3	Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
4	Hassan R, Kreitman RJ, Pastan I and Willingham MC: Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol. 13:243–247. 2005. View Article : Google Scholar : PubMed/NCBI
5	Ordóñez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 16:192–197. 2003. View Article : Google Scholar : PubMed/NCBI
6	Ordóñez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 27:1418–1428. 2003. View Article : Google Scholar : PubMed/NCBI
7	Li M, Bharadwaj U, Zhang R, et al: Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 7:286–296. 2008. View Article : Google Scholar : PubMed/NCBI
8	Einama T, Kamachi H, Nishihara H, et al: Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 40:1276–1282. 2011. View Article : Google Scholar : PubMed/NCBI
9	Einama T, Homma S, Kamachi H, et al: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. May 29–2012. View Article : Google Scholar : PubMed/NCBI
10	Kawamata F, Homma S, Kamachi H, et al: C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J Gastroenterol. 49:81–92. 2014. View Article : Google Scholar
11	Kawamata F, Kamachi H, Einama T, et al: Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol. 41:2109–2118. 2012.PubMed/NCBI
12	Bosman FT, Carneiro F, Hruban RH and Theise ND: Tumors of the pancreas. WHO Classification of Tumours of the Digestive System. 4th edition. IARC press; Lyon: pp. 304–313. 2010
13	Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res. 10:3937–3942. 2004. View Article : Google Scholar : PubMed/NCBI
14	Cheng WF, Huang CY, Chang MC, et al: High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer. 100:1144–1153. 2009. View Article : Google Scholar : PubMed/NCBI
15	Bharadwaj U, Marin-Muller C, Li M, Chen C and Yao Q: Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis. 32:1013–1024. 2011. View Article : Google Scholar : PubMed/NCBI
16	Bharadwaj U, Marin-Muller C, Li M, Chen C and Yao Q: Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 10:1062011. View Article : Google Scholar
17	Inami K, Abe M, Takeda K, et al: Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Cancer Sci. 101:969–974. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sugiyama M, Izumisato Y, Abe N, et al: Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg. 90:1244–1249. 2003. View Article : Google Scholar : PubMed/NCBI
19	Schmidt CM, White PB, Waters JA, et al: Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg. 246:644–651. 2007. View Article : Google Scholar : PubMed/NCBI
20	Nara S, Onaya H, Hiraoka N, et al: Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases. Pancreas. 38:8–16. 2009. View Article : Google Scholar